The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.

The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.

The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.

The present invention relates to the field of tuberculosis vaccines, and specifically relates to a tuberculosis vaccine, a preparation method thereof, and a use thereof. To address the problem of existing vaccines being unsuitable for patients having weak immunity, the present invention provides a preparation method for a tuberculosis vaccine: first obtaining mycobacterium single cell bacteria, and using low dosage radiation to irradiate cyclically the mycobacterium single cell bacteria, so as to obtain the tuberculosis vaccine. The present invention completely retains all of the antigen characteristics of the bacteria, and can more rapidly stimulate stronger specific immune responses, thereby achieving effective and long-lasting immunity. The vaccine prepared using the present invention has low toxicity, is rapid-acting and safer, and can be used for the prevention and treatment of tuberculosis for people having immunodeficiency.

An isolated recombinant influenza virus is provided having PA, PB1, PB2, NP, NS, M, NA and HA viral segments, wherein the PB1 viral segment encodes a PB1 with a residue other than isoleucine at position 711 or the M viral segment encodes a M1 with a residue other than methionine at position 128, wherein the recombinant influenza virus has enhanced replication relative to a corresponding influenza virus having a PB1 viral segment that encodes a PB1 with an isoleucine at position 711 or having a M viral segment that encodes a M1 with methionine at position 128, as well as methods of making and using the virus.

A method of treating cancer in a subject that includes administering in situ to the cancer a therapeutically effective amount of a plant virus or virus-like particle to the subject.

A method and system for the treatment of honey bees (Apis mellifera), bats, and butterflies protects them from various life threatening conditions, including Colony Collapse Disorder, white nose syndrome, etc. and in particular, provides honey bees, bats and butterflies with the ability to assimilate and degrade pesticides such as neonicotinoids and fipronil.

The present invention relates to formulations and method of drug administration useful for treating lung cancer (in particular, non-small lung cancer) by administering a therapeutic antibody drug with a soft mist inhaler or by nebulization.